Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*Julien Carvelli, Pierre‐Yves Cordier, Jérôme Allardet-Servent et al.|Critical Care Medicine|2022Cited by 29
Complement augments antibody neutralization of SARS-CoV-2 variantsMartin Groznica, Stephane Marot, Pierre Rosenbaum et al.|Science Translational Medicine|2026Cited by 0